利妥昔单抗对系统性红斑狼疮患者长期损伤累积的影响
本研究匹配性别和发病年龄,纳入380例SLE患者(利妥昔单抗组190例、标准免疫抑制治疗对照组190例),以SLICC/ACR损伤指数(DI)评估损伤。利妥昔单抗组基线DI更高(1.3 vs 0.9;P=0.02),但二次分析中两组DI均值无统计学差异(0.4 vs 0.6;P=0.33),对照组DI进展比例高于利妥昔单抗组(58.2% vs 44.2%)。
要点
- 利妥昔单抗组基线SLICC/ACR DI高于对照组(1.3 vs 0.9;P=0.02)。
- 二次分析中两组DI均值无统计学差异(0.4 vs 0.6;P=0.33)。
- 对照组DI进展比例高于利妥昔单抗组(58.2% vs 44.2%)。
核心结论
- 利妥昔单抗是SLE的有效治疗选择,尤其适用于难治性或危及生命的表现。
- 利妥昔单抗组初始损伤更高,但损伤进展速度较标准治疗组更慢。
研究设计与样本
- 匹配性别和发病年龄的对照研究,纳入380例SLE患者,利妥昔单抗组190例、标准免疫抑制治疗对照组190例。
- 另对111例患者进行二次分析以评估DI进展。
主要发现
- 多数患者为女性(94.1%)和高加索人(45.4%)。
- 利妥昔单抗组严重疾病表现更多,抗dsDNA抗体滴度更高(86 U/ml vs 62 U/ml;P=0.012)。
- 利妥昔单抗组SLICC/ACR DI更高(1.3 vs 0.9;P=0.02)。
- 二次分析中两组SLICC/ACR DI均值无统计学差异(0.4 vs 0.6;P=0.33)。
- 对照组DI进展比例高于利妥昔单抗组(58.2% vs 44.2%)。
关键数值与推荐
- 损伤评估采用SLICC/ACR损伤指数(DI)。
- 抗dsDNA抗体滴度利妥昔单抗组86 U/ml vs 对照组62 U/ml(P=0.012)。
- SLICC/ACR DI利妥昔单抗组1.3 vs 对照组0.9(P=0.02)。
- 二次分析SLICC/ACR DI均值利妥昔单抗组0.4 vs 对照组0.6(P=0.33)。
- DI进展比例对照组58.2% vs 利妥昔单抗组44.2%。
临床怎么用
- 原文结论认为利妥昔单抗是SLE的有效治疗选择,尤其适用于难治性或危及生命的表现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: B-cell depletion therapy has been used for over two decades to treat SLE, but there is a lack of studies reporting its impact on damage progression. This study aims to assess the effectiveness of rituximab in slowing damage acquisition. METHODS: We selected 380 patients 190 treated with rituximab and 190 controls, based on matched sex and age of onset, with standard immunosuppressive therapies-to compare the damage they developed, assessed by the SLICC/ACR Damage Index (DI). A secondary analysis of 111 patients was conducted to evaluate DI progression. RESULTS: The majority of patients were female (94.1%) and Caucasian (45.4%). Severe disease manifestations and higher titres of anti-dsDNA antibodies (86 U/ml vs 62 U/ml; P = 0.012) were seen in the rituximab group, in which SLICC/ACR DI was also higher (1.3 vs 0.9; P = 0.02). In the secondary analysis the SLICC/ACR DI mean had no statistical difference between the two groups (0.4 vs 0.6; P = 0.33), but we identified a statistical significance between the two groups regarding their DI progression (58.2% in the control group vs 44.2% in the rituximab). CONCLUSION: As an effective B-cell depleting therapy, rituximab is a valid therapeutic option for SLE patients, especially in those with refractory or life-threatening manifestations. While patients treated with rituximab initially had higher damage, their rate of damage progression was slower compared with those receiving standard therapies.
引用
- da Silva Brito A, Miranda S, Moitinho de Almeida T, et al. Effect of rituximab on long-term damage acquisition in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2025. PMID: 40372703. doi:10.1093/rheumatology/keaf248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。